The Rationale for Exploring Brentuximab Vedotin Plus AVD in Hodgkin Lymphoma

December 19, 2017
Tatyana Feldman, MD

Tatyana Feldman, MD, John Theurer Cancer Center, Hackensack University Medical Center, discusses the phase III Echelon-1 study, which found brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (AVD) demonstrated superior modified progression-free survival (PFS) versus ABVD in patients with previously untreated stage III or IV Hodgkin lymphoma.